Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lauren Janes is active.

Publication


Featured researches published by Lauren Janes.


Nature Medicine | 2001

Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis

Mihaela Skobe; Thomas Hawighorst; David G. Jackson; Remko Prevo; Lauren Janes; Paula Velasco; Lucia Riccardi; Kari Alitalo; Kevin P. Claffey; Michael Detmar

Metastasis of breast cancer occurs primarily through the lymphatic system, and the extent of lymph node involvement is a key prognostic factor for the disease. Whereas the significance of angiogenesis for tumor progression has been well documented, the ability of tumor cells to induce the growth of lymphatic vessels (lymphangiogenesis) and the presence of intratumoral lymphatic vessels have been controversial. Using a novel marker for lymphatic endothelium, LYVE-1, we demonstrate here the occurrence of intratumoral lymphangiogenesis within human breast cancers after orthotopic transplantation onto nude mice. Vascular endothelial growth factor (VEGF)-C overexpression in breast cancer cells potently increased intratumoral lymphangiogenesis, resulting in significantly enhanced metastasis to regional lymph nodes and to lungs. The degree of tumor lymphangiogenesis was highly correlated with the extent of lymph node and lung metastases. These results establish the occurrence and biological significance of intratumoral lymphangiogenesis in breast cancer and identify VEGF-C as a molecular link between tumor lymphangiogenesis and metastasis.


The EMBO Journal | 2000

Thrombospondin‐1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice

Michael Streit; Paula Velasco; Lucia Riccardi; Lisa A. Spencer; Lawrence F. Brown; Lauren Janes; Bernhard Lange-Asschenfeldt; Kiichiro Yano; Thomas Hawighorst; Luisa Iruela-Arispe; Michael Detmar

The function of the endogenous angiogenesis inhibitor thrombospondin‐1 (TSP‐1) in tissue repair has remained controversial. We established transgenic mice with targeted overexpression of TSP‐1 in the skin, using a keratin 14 expression cassette. TSP‐1 transgenic mice were healthy and fertile, and did not show any major abnormalities of normal skin vascularity, cutaneous vascular architecture, or microvascular permeability. However, healing of full‐thickness skin wounds was greatly delayed in TSP‐1 transgenic mice and was associated with reduced granulation tissue formation and highly diminished wound angiogenesis. Moreover, TSP‐1 potently inhibited fibroblast migration in vivo and in vitro. These findings demonstrate that TSP‐1 preferentially interfered with wound healing‐associated angiogenesis, rather than with the angiogenesis associated with normal development and skin homeostasis, and suggest that therapeutic application of angiogenesis inhibitors might potentially be associated with impaired wound vascularization and tissue repair.


Oncogene | 2002

Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice

Thomas Hawighorst; Hajimu Oura; Michael Streit; Lauren Janes; Lynh Nguyen; Lawrence F. Brown; Guillermo Oliver; David G. Jackson; Michael Detmar

The roles played by the endogenous angiogenesis inhibitor thrombospondin-1 (TSP-1) in the early stages of multi-step carcinogenesis and in the control of hematogenous versus lymphatic metastasis are unknown. To investigate these issues we compared tumor development in normal mice and in transgenic mice with targeted overexpression of TSP-1 in the epidermis following a standard two-step chemical skin carcinogenesis regimen. Overexpression of TSP-1 resulted in delayed and reduced development of premalignant epithelial hyperplasias, but did not inhibit the malignant conversion to squamous cell carcinomas. TSP-1 overexpression also suppressed tumor angiogenesis and distant organ metastasis, but failed to inhibit tumor-associated lymphangiogenesis or lymphatic tumor spread to regional lymph nodes. Concomitant with these results, we found that the endothelial TSP-1 receptor CD36 was mostly absent from cutaneous lymphatic vessels. Our findings indicate the potential use of TSP-1 for the prevention of premalignant stages of tumorigenesis and are likely to have implications for the further development of anti-angiogenic cancer therapies.


Nature Communications | 2016

A role of stochastic phenotype switching in generating mosaic endothelial cell heterogeneity.

Lei Yuan; Gary C. Chan; David Beeler; Lauren Janes; Katherine Spokes; Harita Dharaneeswaran; Anahita Mojiri; William J. Adams; Tracey E. Sciuto; Guillermo García-Cardeña; Grietje Molema; Peter M. Kang; Nadia Jahroudi; Philip A. Marsden; Ann M. Dvorak; Erzsébet Ravasz Regan; William C. Aird

Previous studies have shown that biological noise may drive dynamic phenotypic mosaicism in isogenic unicellular organisms. However, there is no evidence for a similar mechanism operating in metazoans. Here we show that the endothelial-restricted gene, von Willebrand factor (VWF), is expressed in a mosaic pattern in the capillaries of many vascular beds and in the aorta. In capillaries, the mosaicism is dynamically regulated, with VWF switching between ON and OFF states during the lifetime of the animal. Clonal analysis of cultured endothelial cells reveals that dynamic mosaic heterogeneity is controlled by a low-barrier, noise-sensitive bistable switch that involves random transitions in the DNA methylation status of the VWF promoter. Finally, the hearts of VWF-null mice demonstrate an abnormal endothelial phenotype as well as cardiac dysfunction. Together, these findings suggest a novel stochastic phenotype switching strategy for adaptive homoeostasis in the adult vasculature.


Circulation Research | 2014

FoxO1-Mediated Activation of Akt Plays a Critical Role in Vascular Homeostasis

Harita Dharaneeswaran; Md. Ruhul Abid; Lei Yuan; Dylan Dupuis; David Beeler; Katherine Spokes; Lauren Janes; Tracey E. Sciuto; Peter M. Kang; Shou-Ching Jaminet; Ann M. Dvorak; Marianne A. Grant; Erzsébet Ravasz Regan; William C. Aird

Rationale: Forkhead box-O transcription factors (FOXOs) transduce a wide range of extracellular signals, resulting in changes in cell survival, cell cycle progression, and several cell type-specific responses. FOXO1 is expressed in many cell types, including endothelial cells (ECs). Previous studies have shown that Foxo1 knockout in mice results in embryonic lethality at E11 because of impaired vascular development. In contrast, somatic deletion of Foxo1 is associated with hyperproliferation of ECs. Thus, the precise role of FOXO1 in the endothelium remains enigmatic. Objective: To determine the effect of endothelial-specific knockout and overexpression of FOXO1 on vascular homeostasis. Methods and Results: We show that EC-specific disruption of Foxo1 in mice phenocopies the full knockout. Although endothelial expression of FOXO1 rescued otherwise Foxo1-null animals, overexpression of constitutively active FOXO1 resulted in increased EC size, occlusion of capillaries, elevated peripheral resistance, heart failure, and death. Knockdown of FOXO1 in ECs resulted in marked inhibition of basal and vascular endothelial growth factor–induced Akt-mammalian target of rapamycin complex 1 (mTORC1) signaling. Conclusions: Our findings suggest that in mice, endothelial expression of FOXO1 is both necessary and sufficient for embryonic development. Moreover, FOXO1-mediated feedback activation of Akt maintains growth factor responsive Akt/mTORC1 activity within a homeostatic range.


Blood | 2011

Vascular bed–specific regulation of the von Willebrand factor promoter in the heart and skeletal muscle

Ju Liu; Lei Yuan; Grietje Molema; Erzsébet Ravasz Regan; Lauren Janes; David Beeler; Katherine Spokes; Yoshiaki Okada; Takashi Minami; Peter Oettgen; William C. Aird

A region of the human von Willebrand factor (VWF) gene between -2812 and the end of the first intron (termed vWF2) was previously shown to direct expression in the endothelium of capillaries and a subset of larger blood vessels in the heart and skeletal muscle. Here, our goal was to delineate the DNA sequences responsible for this effect. A series of constructs containing deletions or mutations of vWF2 coupled to LacZ were targeted to the Hprt locus of mice, and the resulting animals were analyzed for reporter gene expression. The findings demonstrate that DNA sequences between -843 and -620 are necessary for expression in capillary but not large vessel endothelium in heart and skeletal muscle. Further, expression of VWF in capillaries and larger vessels of both tissues required the presence of a native or heterologous intron. In vitro assays implicated a role for ERG-binding ETS motif at -56 in mediating basal expression of VWF. In Hprt-targeted mice, mutation of the ETS consensus motif resulted in loss of LacZ expression in the endothelium of the heart and skeletal muscle. Together, these data indicate that distinct DNA modules regulate vascular bed-specific expression of VWF.


Blood | 2009

Differential roles for ETS, CREB and EGR binding sites in mediating VEGF receptor 1 expression in vivo

Enjing Jin; Ju Liu; Jun-ichi Suehiro; Lei Yuan; Yoshiaki Okada; Vesna Nikolova-Krstevski; Kiichiro Yano; Lauren Janes; David Beeler; Katherine Spokes; Dan Li; Erzsébet Ravasz Regan; Shou-Ching Shih; Peter Oettgen; Takashi Minami; William C. Aird

Vascular endothelial growth factor receptor 1 (VEGFR1) is a marker for endothelial-specific gene expression. We previously reported that the human VEGFR1 promoter (between -748 and +284) contains information for expression in the intact endothelium of transgenic mice. The objective of this study was to dissect the cis-regulatory elements underlying VEGFR1 promoter activity in vitro and in vivo. In primary endothelial cells, binding sites for E74-like factor 1 (ELF-1; between -49 and -52), cyclic adenosine monophosphate response element binding (CREB; between -74 and -81), and early growth response factor 1/3 (EGR-1/3; between -16 to -25) were shown to play a positive role in gene transcription, whereas a putative E26 transformation-specificsequence (ETS) motif between -36 and -39 had a net negative effect on promoter activity. When targeted to the Hprt locus of mice, mutations of the ELF-1 binding site and the CRE element reduced promoter activity in the embryonic vasculature and resulted in a virtual loss of expression in adult endothelium. Postnatally, the EGR binding site mutant displayed significantly reduced promoter activity in a subset of vascular beds. In contrast, mutation of the -39 ETS site resulted in increased LacZ staining in multiple vascular beds. Together, these results provide new insights into the transcriptional regulatory mechanisms of VEGFR1.


Blood | 2013

Role of RNA splicing in mediating lineage-specific expression of the von Willebrand factor gene in the endothelium

Lei Yuan; Lauren Janes; David Beeler; Katherine Spokes; Joshua D. Smith; Dan Li; Shou-Ching Jaminet; Peter Oettgen; William C. Aird

We previously demonstrated that the first intron of the human von Willebrand factor (vWF) is required for gene expression in the endothelium of transgenic mice. Based on this finding, we hypothesized that RNA splicing plays a role in mediating vWF expression in the vasculature. To address this question, we used transient transfection assays in human endothelial cells and megakaryocytes with intron-containing and intronless human vWF promoter-luciferase constructs. Next, we generated knockin mice in which LacZ was targeted to the endogenous mouse vWF locus in the absence or presence of the native first intron or heterologous introns from the human β-globin, mouse Down syndrome critical region 1, or hagfish coagulation factor X genes. In both the in vitro assays and the knockin mice, the loss of the first intron of vWF resulted in a significant reduction of reporter gene expression in endothelial cells but not megakaryocytes. This effect was rescued to varying degrees by the introduction of a heterologous intron. Intron-mediated enhancement of expression was mediated at a posttranscriptional level. Together, these findings implicate a role for intronic splicing in mediating lineage-specific expression of vWF in the endothelium.


Blood | 2008

A GABP-binding element in the Robo4 promoter is necessary for endothelial expression in vivo

Yoshiaki Okada; Enjing Jin; Vesna Nikolova-Krstevski; Kiichiro Yano; Ju Liu; David Beeler; Katherine Spokes; Mie Kitayama; Nobuaki Funahashi; Takefumi Doi; Lauren Janes; Takashi Minami; Peter Oettgen; William C. Aird


Arteriosclerosis, Thrombosis, and Vascular Biology | 2015

Abstract 44: Organ-specific Stochastic Phenotype Switching is Required for Endothelial Health

Lei Yuan; Gary C. Chan; David Beeler; Lauren Janes; Katherine Spokes; Anahita Mojiri; William J Adams; Tracey E. Sciuto; Guillermo García-Cardeña; Grietje Molema; Nadia Jahroudi; Philip A. Marsden; Ann M. Dvorak; Erzsébet Ravasz Regan; William C. Aird

Collaboration


Dive into the Lauren Janes's collaboration.

Top Co-Authors

Avatar

David Beeler

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

William C. Aird

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Katherine Spokes

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Lei Yuan

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Erzsébet Ravasz Regan

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Peter Oettgen

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Ann M. Dvorak

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Dan Li

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ju Liu

Beth Israel Deaconess Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge